BRPI0813840A2 - métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio - Google Patents

métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio

Info

Publication number: BRPI0813840A2
Authority: BR; Brazil
Prior art keywords: transporter; inhibitors; preparation; methods; compounds useful
Prior art date: 2007-07-26

Application number

BRPI0813840A

Other languages

English (en)

Inventor

alden harrison Bryce

Zhang Haiming

Yan Jie

Mangzhu Zhao Matthew

Cathleen Goodwin Nicole

Song Qiuling

Mabon Ross

Iimura Shinya

Wu Wenxue

Original Assignee

Lexicon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-26

Filing date

2008-07-17

Publication date

2017-06-06

2008-07-17 Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc

2017-06-06 Publication of BRPI0813840A2 publication Critical patent/BRPI0813840A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Crystallography & Structural Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0813840A 2007-07-26 2008-07-17 métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio BRPI0813840A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US95212207P	2007-07-26	2007-07-26
PCT/US2008/070250 WO2009014970A1 (en)	2007-07-26	2008-07-17	Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0813840A2 true BRPI0813840A2 (pt)	2017-06-06

Family

ID=39877996

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0813840A BRPI0813840A2 (pt)	2007-07-26	2008-07-17	métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio

Country Status (24)

Country	Link
US (2)	US8026347B2 (pt)
EP (1)	EP2183263B1 (pt)
JP (2)	JP5653213B2 (pt)
KR (1)	KR101663324B1 (pt)
CN (1)	CN101801989B (pt)
AR (2)	AR067701A1 (pt)
AT (1)	ATE530558T1 (pt)
AU (1)	AU2008279424B2 (pt)
BR (1)	BRPI0813840A2 (pt)
CA (1)	CA2694029C (pt)
CL (1)	CL2008002169A1 (pt)
CO (1)	CO6260141A2 (pt)
DK (1)	DK2183263T3 (pt)
EA (1)	EA017411B1 (pt)
EC (1)	ECSP109987A (pt)
ES (1)	ES2375800T3 (pt)
IL (1)	IL203209A (pt)
NZ (1)	NZ582536A (pt)
PL (1)	PL2183263T3 (pt)
PT (1)	PT2183263E (pt)
TW (2)	TWI419886B (pt)
UA (1)	UA107175C2 (pt)
WO (1)	WO2009014970A1 (pt)
ZA (1)	ZA201000219B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
MX2011000637A (es)	2008-07-15	2011-05-02	Theracos Inc	Derivados deuretados de bencilbenceno y metodos de uso.
TWI472521B (zh) *	2008-07-17	2015-02-11	Lexicon Pharmaceuticals Inc	（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
MX2011002166A (es)	2008-08-28	2011-04-07	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
EA021983B1 (ru)	2009-11-02	2015-10-30	Пфайзер Инк.	Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011060256A2 (en)	2009-11-13	2011-05-19	Bristol-Myers Squibb Company	Bilayer tablet formulations
ES2693686T3 (es)	2009-11-13	2018-12-13	Astrazeneca Ab	Formulaciones de comprimidos de liberación inmediata
BR112012011274A2 (pt)	2009-11-13	2016-04-12	Astrazeneca Uk Ltd	formulação de metformina de massa reduzida e sua combinação
TWI562775B (en) *	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011153712A1 (en) *	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
AU2011295837B2 (en)	2010-09-03	2015-06-18	Astrazeneca Uk Limited	Drug formulations using water soluble antioxidants
ES2801725T3 (es)	2011-02-01	2021-01-12	Bristol Myers Squibb Co	Formulaciones farmacéuticas que incluyen un compuesto de amina
ES2719656T3 (es)	2011-06-01	2019-07-11	Green Cross Corp	Derivados de difenilmetano novedosos como inhibidores del SGLT2
MX2013014135A (es)	2011-06-03	2014-01-23	Boehringer Ingelheim Int	Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
RU2015123738A (ru) *	2012-11-20	2017-01-10	Лексикон Фармасьютикалз, Инк.	Ингибиторы котранспортера натрий-глюкозы 1
PL2981269T3 (pl)	2013-04-04	2024-02-05	Boehringer Ingelheim Vetmedica Gmbh	Leczenie zaburzeń metabolicznych u zwierząt koniowatych
US9394329B2 (en)	2013-09-27	2016-07-19	Sunshine Lake Pharma Co., Ltd.	Glucopyranosyl derivatives and their uses in medicine
WO2015051484A1 (en)	2013-10-12	2015-04-16	Theracos, Inc.	Preparation of hydroxy-benzylbenzene derivatives
LT3862003T (lt)	2013-12-17	2023-12-27	Boehringer Ingelheim Vetmedica Gmbh	Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams
EA032558B1 (ru)	2014-01-23	2019-06-28	Бёрингер Ингельхайм Ветмедика Гмбх	Лечение метаболических расстройств у представителей собачьих
MX376911B (es)	2014-04-01	2025-03-07	Boehringer Ingelheim Vetmedica Gmbh	Inhibidores de sglt2 para usarse en el tratamiento de trastornos metabolicos en animales equinos.
EP3197429B1 (en)	2014-09-25	2024-05-22	Boehringer Ingelheim Vetmedica GmbH	Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN109195980B (zh) *	2016-05-25	2022-05-17	苏州科睿思制药有限公司	一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
US10793588B2 (en) *	2016-05-28	2020-10-06	Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd.	Crystal form of sodium-glucose cotransporter 2 inhibitor
HRP20211670T8 (hr)	2016-06-17	2022-03-18	Daewoong Pharmaceutical Co., Ltd.	Derivat difenilmetana u kristalnom obliku
KR20190070956A (ko)	2016-10-19	2019-06-21	베링거 인겔하임 인터내셔날 게엠베하	Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
CN107540685B (zh) *	2017-09-04	2020-05-05	杭州科巢生物科技有限公司	一种Sotagliflozin的制备方法及其中间体
WO2019201752A1 (en)	2018-04-17	2019-10-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN108675976B (zh) *	2018-05-14	2020-07-14	浙江宏元药业股份有限公司	一种6-卤代葡萄糖碳苷及其制备方法和应用
EP3838894B1 (en)	2018-08-13	2024-03-13	Daewoong Pharmaceutical Co., Ltd.	Method for producing intermediate useful for synethesis of sglt inhibitor
CN110818722B (zh) *	2018-08-14	2022-12-02	苏州鹏旭医药科技有限公司	三种化合物及其制备方法和在合成索格列净中的用途
WO2020089025A1 (en)	2018-10-29	2020-05-07	Boehringer Ingelheim International Gmbh	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
PE20211467A1 (es)	2018-10-29	2021-08-05	Boehringer Ingelheim Int	Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos
EP3771480A1 (en) *	2019-08-01	2021-02-03	Lexicon Pharmaceuticals, Inc.	Continuous process for preparing the crystalline form ii of sotagliflozin
JP7441946B2 (ja)	2019-11-28	2024-03-01	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用
MX2022010090A (es)	2020-02-17	2022-09-02	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
KR20240041966A (ko)	2021-07-28	2024-04-01	베링거잉겔하임베트메디카게엠베하	고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
CN117715639A (zh)	2021-07-28	2024-03-15	勃林格殷格翰动物保健有限公司	Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
EP4376819A1 (en)	2021-07-28	2024-06-05	Boehringer Ingelheim Vetmedica GmbH	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN113880701A (zh) *	2021-10-10	2022-01-04	浙江司太立制药股份有限公司	一种抗糖尿病药物中间体及其制备方法
TW202412756A (zh)	2022-05-25	2024-04-01	德商百靈佳殷格翰維美迪加股份有限公司	包含sglt-2抑制劑之水性醫藥組合物
CN120857933A (zh)	2023-03-06	2025-10-28	勃林格殷格翰动物保健有限公司	用于递送特别包含一或多种sglt-2抑制剂的液体药物组合物的系统
AU2024277852A1 (en)	2023-05-24	2025-10-16	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
TW202508593A (zh)	2023-05-24	2025-03-01	德商百靈佳殷格翰維美迪加股份有限公司	包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
WO2025160910A1 (en) *	2024-02-01	2025-08-07	New Wish Biotechnology Wuxi Co., Ltd.	Indazole compound and pharmaceutical composition, preparation method and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5753789A (en) *	1996-07-26	1998-05-19	Yale University	Oligonucleotides containing L-nucleosides
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
WO2001068660A1 (en)	2000-03-17	2001-09-20	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
CA2429833A1 (en)	2000-11-30	2002-06-06	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6936590B2 (en)	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
JP2004536047A (ja) *	2001-04-11	2004-12-02	ブリストル−マイヤーズ　スクイブ　カンパニー	糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
US6562791B1 (en)	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
WO2003087119A1 (en) *	2002-04-12	2003-10-23	Achillion Pharmaceuticals, Inc.	METHOD FOR SYNTHESIZING β-L-FLUORO-2´,3´DIDEHYDROCYTIDINE (β-L-FD4C)
US7414072B2 (en)	2002-08-09	2008-08-19	Taisho Pharmaceutical Co., Ltd.	Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
CA2512389A1 (en) *	2003-01-03	2004-07-29	Bristol-Myers Squibb Company	Methods of producing c-aryl glucoside sglt2 inhibitors
US7368475B2 (en) *	2003-03-12	2008-05-06	Kemin Pharma Bvba	Furanose-type bicyclic carbohydrates with biological activity
ES2363941T3 (es)	2003-03-14	2011-08-19	Astellas Pharma Inc.	Derivados de c-glucósido para el tratamiento de diabetes.
WO2006018150A1 (de) *	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2595257A1 (en)	2005-02-23	2006-08-31	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
TWI499414B (zh) *	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
WO2008044268A1 (en) *	2006-10-05	2008-04-17	Panasonic Corporation	Transmitter apparatus and transmitting method
US7846945B2 (en) *	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TWI472521B (zh)	2008-07-17	2015-02-11	Lexicon Pharmaceuticals Inc	（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

2008
- 2008-07-17 CN CN200880100489.2A patent/CN101801989B/zh active Active
- 2008-07-17 UA UAA201002095A patent/UA107175C2/ru unknown
- 2008-07-17 PT PT08826634T patent/PT2183263E/pt unknown
- 2008-07-17 NZ NZ582536A patent/NZ582536A/en unknown
- 2008-07-17 ES ES08826634T patent/ES2375800T3/es active Active
- 2008-07-17 US US12/174,722 patent/US8026347B2/en active Active
- 2008-07-17 EP EP08826634A patent/EP2183263B1/en active Active
- 2008-07-17 BR BRPI0813840A patent/BRPI0813840A2/pt active IP Right Grant
- 2008-07-17 JP JP2010518296A patent/JP5653213B2/ja active Active
- 2008-07-17 PL PL08826634T patent/PL2183263T3/pl unknown
- 2008-07-17 KR KR1020107001659A patent/KR101663324B1/ko active Active
- 2008-07-17 AT AT08826634T patent/ATE530558T1/de active
- 2008-07-17 WO PCT/US2008/070250 patent/WO2009014970A1/en not_active Ceased
- 2008-07-17 AU AU2008279424A patent/AU2008279424B2/en active Active
- 2008-07-17 DK DK08826634.1T patent/DK2183263T3/da active
- 2008-07-17 EA EA201070186A patent/EA017411B1/ru not_active IP Right Cessation
- 2008-07-17 CA CA2694029A patent/CA2694029C/en active Active
- 2008-07-21 TW TW097127665A patent/TWI419886B/zh active
- 2008-07-21 TW TW102129521A patent/TWI506024B/zh active
- 2008-07-24 CL CL2008002169A patent/CL2008002169A1/es unknown
- 2008-07-25 AR ARP080103246A patent/AR067701A1/es active IP Right Grant
2010
- 2010-01-10 IL IL203209A patent/IL203209A/en active IP Right Grant
- 2010-01-12 ZA ZA2010/00219A patent/ZA201000219B/en unknown
- 2010-02-23 EC EC2010009987A patent/ECSP109987A/es unknown
- 2010-02-25 CO CO10022864A patent/CO6260141A2/es not_active Application Discontinuation
2011
- 2011-08-11 US US13/207,576 patent/US8293878B2/en active Active
2013
- 2013-08-28 JP JP2013176646A patent/JP5764174B2/ja active Active
2018
- 2018-08-03 AR ARP180102213 patent/AR112669A2/es active IP Right Grant

Also Published As

Publication number	Publication date
EP2183263A1 (en)	2010-05-12
TW201350473A (zh)	2013-12-16
CN101801989A (zh)	2010-08-11
CA2694029C (en)	2016-10-04
PL2183263T3 (pl)	2012-03-30
ZA201000219B (en)	2011-03-30
IL203209A (en)	2014-02-27
US20120095197A1 (en)	2012-04-19
CO6260141A2 (es)	2011-03-22
AR112669A2 (es)	2019-11-27
AU2008279424A1 (en)	2009-01-29
UA107175C2 (uk)	2014-12-10
JP5764174B2 (ja)	2015-08-12
JP5653213B2 (ja)	2015-01-14
ECSP109987A (es)	2010-03-31
DK2183263T3 (da)	2012-01-30
HK1143982A1 (zh)	2011-01-21
EA201070186A1 (ru)	2010-08-30
US8026347B2 (en)	2011-09-27
NZ582536A (en)	2012-01-12
AR067701A1 (es)	2009-10-21
KR101663324B1 (ko)	2016-10-06
EA017411B1 (ru)	2012-12-28
CL2008002169A1 (es)	2009-03-20
ES2375800T3 (es)	2012-03-06
KR20100040869A (ko)	2010-04-21
CN101801989B (zh)	2015-11-25
US8293878B2 (en)	2012-10-23
PT2183263E (pt)	2012-01-11
EP2183263B1 (en)	2011-10-26
TW200914434A (en)	2009-04-01
WO2009014970A1 (en)	2009-01-29
JP2014001230A (ja)	2014-01-09
JP2010534661A (ja)	2010-11-11
AU2008279424B2 (en)	2013-06-13
TWI419886B (zh)	2013-12-21
CA2694029A1 (en)	2009-01-29
US20090030198A1 (en)	2009-01-29
ATE530558T1 (de)	2011-11-15
TWI506024B (zh)	2015-11-01

Publication	Publication Date	Title
BRPI0813840A2 (pt)	2017-06-06	métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio
HUS1900038I1 (hu)	2019-09-30	Nátrium-glükóz kotranszporter-2 inhibitorai és alkalmazási eljárásaik
CR20140154A (es)	2014-07-23	Compuestos para inhibir la progresión mitotica
HUS1600048I1 (hu)	2017-01-30	Készítmény Fabry-kór kezelésére
CY2014012I2 (el)	2015-12-09	Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
BRPI0811635A2 (pt)	2014-11-11	Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CR10562A (es)	2009-03-20	Nuevos derivados de piridazina
DK2042480T3 (da)	2013-05-27	Aminoindan-derivat eller salt deraf
PT1850664E (pt)	2014-03-26	Formulação de cápsulas
BRPI0814115A2 (pt)	2015-02-03	Composição farmacêutica compreendendo composto de 11-deóxi-prostaglandina e método para estabilizar o composto
FI20065708A0 (fi)	2006-11-10	Laitteisto yksillöllisesti muotoiltujen jalkineiden suunnittelemiseksi
BRPI0715732A2 (pt)	2013-09-24	mÉtodo para a preparaÇço de um nanocompàsito de poliÉster
BRPI0814074A2 (pt)	2015-02-03	Método para a fabricação de 4-isopropil-3-metilfenol e sua utilização
EP1910272A4 (en)	2010-08-04	Renin Inhibitors
ITMI20061048A1 (it)	2007-11-30	Procedimento per la preparazione di magnesio boroidruro cristallino
ITMI20060489A1 (it)	2007-09-18	Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
ITMI20052464A1 (it)	2007-06-23	Procedimento per la preparazi9one di norelgestromin norelgestromina
ES1060647Y (es)	2006-02-01	Reposabrazos para facilitar la aplicacion de inyectables
ITMI20061096A1 (it)	2007-12-07	Procedimento per la preparazione di (1-tia-)3-cefem derivati
ITMI20061606A1 (it)	2008-02-10	Procedimento per la preparazione di composti nitrilici
ES1063735Y (es)	2007-03-01	Testero para persiana
ITMI20062515A1 (it)	2008-06-28	Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
ES1063412Y (es)	2007-01-16	Precerco para puertas
ITMI20061364A1 (it)	2008-01-14	Procedimento per la preparazione di delapril
CR9437A (es)	2008-09-09	Procedimiento para la preparacion de moduladores opioides

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-30	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-02-05	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-05-12	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-08-11	B09B	Patent application refused [chapter 9.2 patent gazette]
2020-10-20	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2025-12-02	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.